Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Fig. 2

Local treatment with LTX-315 shows a significant additive antitumor effect when combined with CAELYX®. Animals with established 4 T1 mammary carcinomas were divided into four groups, (i) vehicle controls, (ii) CAELYX®, (iii) LTX-315, or (iv) a combination of LTX-315 and CAELYX®. Palpable tumors were injected twice intratumorally with 1 mg LTX-315 on day 7 and 8 post tumor challenge and 8 mg/kg CAELYX® on day 7. The body weight of all animals remained within the normal range throughout the study (a). Tumor growth curves showed that LTX-315 had a significant additive antitumor effect (Tukey’s multiple comparisons test, p ≤ 0.05) when combined with single-dose CAELYX® compared to monotherapy alone (b), in addition to inducing complete regression in 50% of the treated animals (c), as shown by the Kaplan–Meier survival plot (p < 0.0001)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us